Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 12;22(16):8661.
doi: 10.3390/ijms22168661.

Current and Future Development in Lung Cancer Diagnosis

Affiliations
Review

Current and Future Development in Lung Cancer Diagnosis

Reem Nooreldeen et al. Int J Mol Sci. .

Abstract

Lung cancer is the leading cause of cancer-related deaths in North America and other developed countries. One of the reasons lung cancer is at the top of the list is that it is often not diagnosed until the cancer is at an advanced stage. Thus, the earliest diagnosis of lung cancer is crucial, especially in screening high-risk populations, such as smokers, exposure to fumes, oil fields, toxic occupational places, etc. Based on the current knowledge, it looks that there is an urgent need to identify novel biomarkers. The current diagnosis of lung cancer includes different types of imaging complemented with pathological assessment of biopsies, but these techniques can still not detect early lung cancer developments. In this review, we described the advantages and disadvantages of current methods used in diagnosing lung cancer, and we provide an analysis of the potential use of body fluids as carriers of biomarkers as predictors of cancer development and progression.

Keywords: biomarkers; body fluids; diagnosis; imaging; lung cancer; predictors.

PubMed Disclaimer

Conflict of interest statement

Authors reported no conflict of interest.

References

    1. Mercer R. Canadian Cancer Statistics: A 2020 Special Report on Lung Cancer. Canadian Centre for Applied Research in Cancer Control; Vancouver, BC, Canada: 2020.
    1. Horeweg N., Scholten E.T., de Jong P.A., van der Aalst C.M., Weenink C., Lammers J.-W.J., Nackaerts K., Vliegenthart R., ten Haaf K., Yousaf-Khan U.A., et al. Detection of Lung Cancer through Low-Dose CT Screening (NELSON): A Prespecified Analysis of Screening Test Performance and Interval Cancers. Lancet Oncol. 2014;15:1342–1350. doi: 10.1016/S1470-2045(14)70387-0. - DOI - PubMed
    1. Gartman E.J., Jankowich M.D., Baptiste J., Nici L. A98. Clinical Strategies to Improve Lung Cancer Early Detection: Who Is at Risk Here? American Thoracic Society International Conference Abstracts. American Thoracic Society; New York, NY, USA: 2018. Providence VA lung cancer screening program: Performance: Comparison of local false positive and invasive procedure rates to published trial data; p. A2477.
    1. Kuman V., Abbas A., Fausto N., Robbins S., Cotran R. Robbins and Cotran Pathologic Basis of Disease. Elsevier Saunders; Philadelphia, PA, USA: 2005. p. 759.
    1. Travis W.D. Update on Small Cell Carcinoma and Its Differentiation from Squamous Cell Carcinoma and Other Non-Small Cell Carcinomas. Mod. Pathol. 2012;25:S18–S30. doi: 10.1038/modpathol.2011.150. - DOI - PubMed

Substances

Grants and funding